

4 March 2026

Costs for Yuflyma 40mg (*adalimumab*)

To request the cost for a 12 month treatment for a patient on Yuflyma 40mg (*adalimumab*) under the current direct to patient home delivery model based upon a standard fortnightly dosing schedule.

Belfast Trust hold this information but are unable to disclose this under section 43 of the Freedom of Information Act (commercial interest) as disclosure would be likely to prejudice the Trust and the provider.

Section 43: commercial interest

Section 43 of the Act sets out an exemption from the right to know if:

- The information requested is a trade secret, or
- Release of the information is likely to prejudice the commercial interests of any person. (A person may be an individual, a company, the public authority itself or any other legal entity).

The outcome of the public interest test is that it would not be in the public interest where the disclosure would prejudice the commercial interests of external provider(s): In reaching this decision to withhold some of the information requested, the Trust has considered fully its commitment to ensuring openness and transparency, where reasonably practicable, in all its activities.